SCHEMBL5010630

SCHEMBL5010630

Cc1ccc(-n2nc(C)cc2Nc2ccccc2C(=O)Nc2cccnc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.53
NAMPT P43490 5/20 0.52
MAPT P10636 1/20 0.52
TSHR P16473 2/20 0.51
GAA P10253 1/20 0.49
NR3C1 P04150 1/20 0.48
F10 P00742 1/20 0.48
MAPK13 O15264 1/20 0.48
MAPK12 P53778 1/20 0.48
MAPK11 Q15759 1/20 0.48
MAPK14 Q16539 1/20 0.48
LRRK2 Q5S007 1/20 0.47
PKM P14618 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5011982 0.89 GFER (0.56) GFERMAPTTSHRGAAMAPK13
SCHEMBL5010571 0.83 GFER (0.59) GFERMAPTTSHRGAAPKM
SCHEMBL5012030 0.82 GFER (0.57) GFERMAPTGAAMAPK13MAPK12
SCHEMBL5005260 0.79 GFER (0.62) GFERMAPTGAAKDM4EMEN1
SCHEMBL5008476 0.79 GFER (0.64) GFERMAPTTSHRGAAMEN1
SCHEMBL6340031 0.78 GFER (0.66) GFERMAPTTSHRGAAIRAK4
SCHEMBL5008426 0.78 GFER (0.66) GFERMAPTTSHRGAAF10
SCHEMBL23203460 0.76 KCNJ6 (0.79) NAMPTMAPTTSHRGAAMAPK13
SCHEMBL31688998 0.76 KCNJ6 (0.79) NAMPTMAPTTSHRGAAMAPK13
SCHEMBL27744709 0.74 TSHR (0.67) NAMPTMAPTTSHRGAAF10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2008-03-13 US disclosed
US-7265144-B2 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes IAPP, GLP1R, GPR119 GFER 1604/4885NAMPT 97/4885MAPT 2420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.